Abstract: A human immunoglobulin against Methicillin-resistant Staphylococcus aureus, and human immunoglobulin against Methicillin-resistant Staphylococcus aureus is prepared by collecting plasma of a healthy plasma donor immunized with Methicillin-resistant Staphylococcus aureus vaccine, wherein the Staphylococcus aureus vaccine has a valence of antigen mHla of no less than 1:3,200, valence of antigen IsdB of no less than 1:1,600, valence of antigen MntC of no less than 1:1,600, valence of antigen mSEB of no less than 1:6,400, and valence of antigen SpA5 of no less than 1:400, and total content of IgG monomers and dimers is over 90.0%. The human immunoglobulin against Methicillin-resistant Staphylococcus aureus has high valence and high purity, which can not only have good effects for preventing and treating Methicillin-resistant Staphylococcus aureus infection, but also avoid a problem of drug resistance caused by antibiotic treatment, and has important clinical significance and broad market prospects.

Abstract: Provided is staphylococcus protein A expressed by a mutational Staphylococcus aureus and its coding sequence, as well as a vector, host bacteria, composition or kit which contains the coding sequence of the mutational protein. Also provided is the use of the mutational protein and the composition thereof in the preparation of vaccines, therapeutic antibodies, diagnostic kits and the like, and for the prevention, treatment and detection of infections by Staphylococcus aureus. Also provided are methods for producing, fermenting and purifying the mutational protein.

Abstract: Provided is staphylococcus protein A expressed by a mutational Staphylococcus aureus and its coding sequence, as well as a vector, host bacteria, composition or kit which contains the coding sequence of the mutational protein. Also provided is the use of the mutational protein and the composition thereof in the preparation of vaccines, therapeutic antibodies, diagnostic kits and the like, and for the prevention, treatment and detection of infections by Staphylococcus aureus. Also provided are methods for producing, fermenting and purifying the mutational protein.

Abstract: The invention relates to a recombinant protein used for immunoprophylaxis of human Helicobacter pylori infection and a degradable slow-releasing microsphere-encapsulated oral vaccine preparation prepared from the same, and the preparation method thereof. Said recombinant protein is composed of A2 subunit and B subunit of the LT of enterotoxigenic Escherichia coli and urease B subunit. The vaccine provided in the invention used in human Helicobacter pylori infection is safe and effective and convenient for oral intake.

Abstract: The invention relates to a recombinant protein used for immunoprophylaxis of human Helicobacter pylori infection and a degradable slow-releasing microsphere-encapsulated oral vaccine preparation prepared from the same, and the preparation method thereof. Said recombinant protein is composed of A2 subunit and B subunit of the LT of enterotoxigenic Escherichia coli and urease B subunit. The vaccine provided in the invention used in human Helicobacter pylori infection is safe and effective and convenient for oral intake.